Your browser doesn't support javascript.
loading
Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting.
Lee, Kyung Ho; Han, Tae Sun; Han, Changsu; Bahk, Won-Myong; Lee, Soo-Jung; Patkar, Ashwin A; Masand, Prakash S; Pae, Chi-Un.
Affiliation
  • Lee KH; Departments of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Han TS; Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Han C; Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Bahk WM; Department of Psychiatry, Korea University College of Medicine, Seoul, Korea.
  • Lee SJ; Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Patkar AA; Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Masand PS; Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.
  • Pae CU; Duke-NUS Medical School, Singapore.
Clin Psychopharmacol Neurosci ; 21(3): 594-598, 2023 Aug 31.
Article in En | MEDLINE | ID: mdl-37424426
Objective: This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice. Methods: Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full remission. The primary endpoint was the mean change of Clinical Global Impression-Clinical Benefit (CGI-CB) total scores from baseline to the endpoint. Additional secondary endpoints were also collected. Results: The changes of CGI-CB (Z = -3.073, p = 0.002) and Montgomery-Åsberg Depression Rating Scale (Z = -3.483, p < 0.001) total scores were significantly decreased from baseline to the endpoint, respectively. At the endpoint, the remission rate was 22.6% (n = 18) and 28.6% of patient had improvement in CGI-CB total scores at the endpoint. No significant adverse events were observed. Conclusion: This study has shown additional benefit of AGO treatment as combination or switching agent for MDD patients without full remission in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Psychopharmacol Neurosci Year: 2023 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Psychopharmacol Neurosci Year: 2023 Document type: Article Country of publication: